



November 12, 2020

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of U.S. FDA approval by the Company along with its alliance partner Concord Biotech Limited for Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, to market a generic version of Prograf® Capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

**Rajvardhan
Vishnu Satam**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, o=Personal,
2.5.4.20=e8a002ede68da3b7e41e01d21c2b9062761a29a5f004
91762a5ac549cb034cae, postalCode=400104, st=Maharashtra,
serialNumber=df8e6e60a88c796663c738ea25bfa0b475d195f7
26cd67a2ff09c4242771b2a, cn=Rajvardhan Vishnu Satam
Date: 2020.11.12 14:17:41 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl.: a/a.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin's Alliance Partner Concord Receives U.S. FDA Approval for Tacrolimus Capsules USP

Mumbai, Baltimore, November 12, 2020: Pharma major Lupin Limited (Lupin) in alliance with Concord Biotech Limited (Concord) announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, to market a generic version of Prograf® Capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc.

Tacrolimus Capsules USP are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney or heart transplants, in combination with other immunosuppressants.

Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg (RLD: Prograf®) had an annual sales of approximately USD 303 million in the U.S. (IQVIA MAT September 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91 22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91 22 6640 2532

****Safe Harbor Statement***

Prograf® is a registered trademark of Astellas Pharma Inc.